A citation-based method for searching scientific literature


List of co-cited articles
1056 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
J H Krystal, L P Karper, J P Seibyl, G K Freeman, R Delaney, J D Bremner, G R Heninger, M B Bowers, D S Charney. Arch Gen Psychiatry 1994
19


Recent advances in the phencyclidine model of schizophrenia.
D C Javitt, S R Zukin. Am J Psychiatry 1991
14

Glutamate receptor ion channels: structure, regulation, and function.
Stephen F Traynelis, Lonnie P Wollmuth, Chris J McBain, Frank S Menniti, Katie M Vance, Kevin K Ogden, Kasper B Hansen, Hongjie Yuan, Scott J Myers, Ray Dingledine. Pharmacol Rev 2010
14

NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease.
Pierre Paoletti, Camilla Bellone, Qiang Zhou. Nat Rev Neurosci 2013
13

Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists.
Thomas Papouin, Laurent Ladépêche, Jérôme Ruel, Silvia Sacchi, Marilyne Labasque, Marwa Hanini, Laurent Groc, Loredano Pollegioni, Jean-Pierre Mothet, Stéphane H R Oliet. Cell 2012
441
10

Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction.
Darrick T Balu, Yan Li, Matthew D Puhl, Michael A Benneyworth, Alo C Basu, Shunsuke Takagi, Vadim Y Bolshakov, Joseph T Coyle. Proc Natl Acad Sci U S A 2013
140
10

Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia.
C S Weickert, S J Fung, V S Catts, P R Schofield, K M Allen, L T Moore, K A Newell, D Pellen, X-F Huang, S V Catts,[...]. Mol Psychiatry 2013
160
10

A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia.
Inna Bendikov, Carmit Nadri, Shirly Amar, Rogerio Panizzutti, Joari De Miranda, Herman Wolosker, Galila Agam. Schizophr Res 2007
236
10


Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia.
Kenji Hashimoto, Takeshi Fukushima, Eiji Shimizu, Naoya Komatsu, Hiroyuki Watanabe, Naoyuki Shinoda, Michiko Nakazato, Chikara Kumakiri, Shin-ichi Okada, Hisanori Hasegawa,[...]. Arch Gen Psychiatry 2003
379
9

D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor.
J P Mothet, A T Parent, H Wolosker, R O Brady, D J Linden, C D Ferris, M A Rogawski, S H Snyder. Proc Natl Acad Sci U S A 2000
846
9

Animal models of schizophrenia.
C A Jones, D J G Watson, K C F Fone. Br J Pharmacol 2011
428
9

Glutamate hypothesis in schizophrenia.
Yota Uno, Joseph T Coyle. Psychiatry Clin Neurosci 2019
102
9

Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes.
Juan E Belforte, Veronika Zsiros, Elyse R Sklar, Zhihong Jiang, Gu Yu, Yuqing Li, Elizabeth M Quinlan, Kazu Nakazawa. Nat Neurosci 2010
540
8

De novo mutations in schizophrenia implicate synaptic networks.
Menachem Fromer, Andrew J Pocklington, David H Kavanagh, Hywel J Williams, Sarah Dwyer, Padhraig Gormley, Lyudmila Georgieva, Elliott Rees, Priit Palta, Douglas M Ruderfer,[...]. Nature 2014
8

NMDA receptor hypofunction model of schizophrenia.
J W Olney, J W Newcomer, N B Farber. J Psychiatr Res 1999
706
8


Serine racemase deletion disrupts memory for order and alters cortical dendritic morphology.
L M DeVito, D T Balu, B R Kanter, C Lykken, A C Basu, J T Coyle, H Eichenbaum. Genes Brain Behav 2011
83
8

Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior.
A C Basu, G E Tsai, C-L Ma, J T Ehmsen, A K Mustafa, L Han, Z I Jiang, M A Benneyworth, M P Froimowitz, N Lange,[...]. Mol Psychiatry 2009
213
7

A critical role for NMDA receptors in parvalbumin interneurons for gamma rhythm induction and behavior.
M Carlén, K Meletis, J H Siegle, J A Cardin, K Futai, D Vierling-Claassen, C Rühlmann, S R Jones, K Deisseroth, M Sheng,[...]. Mol Psychiatry 2012
407
7

Schizophrenia risk from complex variation of complement component 4.
Aswin Sekar, Allison R Bialas, Heather de Rivera, Avery Davis, Timothy R Hammond, Nolan Kamitaki, Katherine Tooley, Jessy Presumey, Matthew Baum, Vanessa Van Doren,[...]. Nature 2016
7

Low d-serine levels in schizophrenia: A systematic review and meta-analysis.
Seo-Eun Cho, Kyoung-Sae Na, Seong-Jin Cho, Seung Gul Kang. Neurosci Lett 2016
37
18

Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial.
Chun-Yuan Lin, Sun-Yuan Liang, Yue-Cune Chang, Shuo-Yen Ting, Ching-Ling Kao, Yu-Hsin Wu, Guochuan E Tsai, Hsien-Yuan Lane. World J Biol Psychiatry 2017
50
14

Mechanism of NMDA Receptor Inhibition and Activation.
Shujia Zhu, Richard A Stein, Craig Yoshioka, Chia-Hsueh Lee, April Goehring, Hassane S Mchaourab, Eric Gouaux. Cell 2016
122
7

Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia.
John E Lisman, Joseph T Coyle, Robert W Green, Daniel C Javitt, Francine M Benes, Stephan Heckers, Anthony A Grace. Trends Neurosci 2008
714
7

Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
Hsien-Yuan Lane, Ching-Hua Lin, Michael F Green, Gerhard Hellemann, Chih-Chia Huang, Po-Wei Chen, Rene Tun, Yue-Cung Chang, Guochuan E Tsai. JAMA Psychiatry 2013
133
7

Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Hsien-Yuan Lane, Yue-Cune Chang, Yi-Ching Liu, Chih-Chiang Chiu, Guochuan E Tsai. Arch Gen Psychiatry 2005
209
7


NMDA receptor subunits: diversity, development and disease.
S Cull-Candy, S Brickley, M Farrant. Curr Opin Neurobiol 2001
7

GABAergic interneuron origin of schizophrenia pathophysiology.
Kazu Nakazawa, Veronika Zsiros, Zhihong Jiang, Kazuhito Nakao, Stefan Kolata, Shuqin Zhang, Juan E Belforte. Neuropharmacology 2012
308
7

A polygenic burden of rare disruptive mutations in schizophrenia.
Shaun M Purcell, Jennifer L Moran, Menachem Fromer, Douglas Ruderfer, Nadia Solovieff, Panos Roussos, Colm O'Dushlaine, Kimberly Chambert, Sarah E Bergen, Anna Kähler,[...]. Nature 2014
919
6


De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia.
G Kirov, A J Pocklington, P Holmans, D Ivanov, M Ikeda, D Ruderfer, J Moran, K Chambert, D Toncheva, L Georgieva,[...]. Mol Psychiatry 2012
538
6

High dose D-serine in the treatment of schizophrenia.
Joshua T Kantrowitz, Anil K Malhotra, Barbara Cornblatt, Gail Silipo, Andrea Balla, Raymond F Suckow, Cyril D'Souza, John Saksa, Scott W Woods, Daniel C Javitt. Schizophr Res 2010
158
6

Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms.
Joshua T Kantrowitz, Michael L Epstein, Migyung Lee, Nayla Lehrfeld, Karen A Nolan, Constance Shope, Eva Petkova, Gail Silipo, Daniel C Javitt. Schizophr Res 2018
52
11

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Guochuan Tsai, Hsien-Yuan Lane, Pinchen Yang, Mian-Yoon Chong, Nicholas Lange. Biol Psychiatry 2004
259
6

Common polygenic variation contributes to risk of schizophrenia and bipolar disorder.
Shaun M Purcell, Naomi R Wray, Jennifer L Stone, Peter M Visscher, Michael C O'Donovan, Patrick F Sullivan, Pamela Sklar. Nature 2009
6

D-serine added to antipsychotics for the treatment of schizophrenia.
G Tsai, P Yang, L C Chung, N Lange, J T Coyle. Biol Psychiatry 1998
502
6

Serine racemase is predominantly localized in neurons in mouse brain.
Kazushi Miya, Ran Inoue, Yoshimi Takata, Manabu Abe, Rie Natsume, Kenji Sakimura, Kazuhisa Hongou, Toshio Miyawaki, Hisashi Mori. J Comp Neurol 2008
177
6

Glutamate receptor dysfunction and schizophrenia.
J W Olney, N B Farber. Arch Gen Psychiatry 1995
6

Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials.
Y Iwata, S Nakajima, T Suzuki, R S E Keefe, E Plitman, J K Chung, F Caravaggio, M Mimura, A Graff-Guerrero, H Uchida. Mol Psychiatry 2015
62
9


NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update.
Daniela Cadinu, Ben Grayson, Giovanni Podda, Michael K Harte, Nazanin Doostdar, Joanna C Neill. Neuropharmacology 2018
78
7


NMDA receptor and schizophrenia: a brief history.
Joseph T Coyle. Schizophr Bull 2012
257
6

The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
Robert W Buchanan, Daniel C Javitt, Stephen R Marder, Nina R Schooler, James M Gold, Robert P McMahon, Uriel Heresco-Levy, William T Carpenter. Am J Psychiatry 2007
293
6

NMDAR Hypofunction Animal Models of Schizophrenia.
Gloria Lee, Yi Zhou. Front Mol Neurosci 2019
40
15

Identity of endogenous NMDAR glycine site agonist in amygdala is determined by synaptic activity level.
Yan Li, Silvia Sacchi, Loredano Pollegioni, Alo C Basu, Joseph T Coyle, Vadim Y Bolshakov. Nat Commun 2013
57
8

Pyramidal cell selective ablation of N-methyl-D-aspartate receptor 1 causes increase in cellular and network excitability.
Valerie M Tatard-Leitman, Catherine R Jutzeler, Jimmy Suh, John A Saunders, Eddie N Billingslea, Susumu Morita, Rachel White, Robert E Featherstone, Rabindranath Ray, Pavel I Ortinski,[...]. Biol Psychiatry 2015
69
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.